Literature DB >> 23039378

Mohs micrographic surgery for basal cell carcinomas: appropriateness of 'Rotterdam' criteria and predictive factors for three or more stages.

S C Flohil1, A M J M van Dorst, T Nijsten, H A Martino Neumann, K Munte.   

Abstract

BACKGROUND: In the Netherlands basal cell carcinomas (BCC) are eligible for Mohs microscopic surgery (MMS) if certain criteria are fulfilled.
OBJECTIVE: To study the MMS indication criteria practised at the department of dermatology of the Erasmus University Medical Center, Rotterdam and to identify predictive factors for extensive subclinical tumour spread among BCCs eligible for MMS.
METHODS: Pre-operative patient and tumour characteristics were derived retrospectively between January 2nd 2006 and December 28th 2009 from 1174 patient records, accounting for 1464 BCCs. Multivariate logistic regression models were used to calculate crude and adjusted odds ratios (OR) with 95% confidence intervals (CI) for one vs. two or more stages and for narrow (≤ 2 stages) vs. extensive subclinical spread (≥ 3 stages).
RESULTS: H-zone location [adjusted OR 1.51 (95% CI 1.16-1.96)], recurrent tumour [adjusted OR 1.50 (95% CI 1.11-2.02)], aggressive subtype [adjusted OR 1.25 (95% CI 1.01-1.56)] and tumour size ≥ 11 mm [adjusted OR 1.53 (95% CI 1.20-1.96)] were significantly associated with two or more stages. Predictive factors for extensive subclinical spread were recurrent tumour [adjusted OR 2.26 (95% CI 1.61-3.17)], tumour size ≥ 21 mm [adjusted OR 1.69 (95% CI 1.13-2.51)] and location in the H-zone [adjusted OR 1.68 (95% CI 1.15-2.46)].
CONCLUSION: 'Rotterdam' indication criteria used for MMS are appropriate. Predictors for extensive subclinical spread are important for patients' and surgeons' expectations prior to the operation about time span, defect size, reconstruction and possible associated morbidity.
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2012        PMID: 23039378     DOI: 10.1111/j.1468-3083.2012.04696.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Response to Rogers et al.

Authors:  Robert S Stern
Journal:  J Invest Dermatol       Date:  2013-10-30       Impact factor: 8.551

2.  Patient indications for Mohs micrographic surgery: a clinical practice guideline.

Authors:  C Murray; D Sivajohanathan; T P Hanna; S Bradshaw; N Solish; B Moran; R Hekkenberg; A C Wei; T Petrella
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

3.  Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry.

Authors:  Lindy Paulina Johanna Arts; Rick Waalboer-Spuij; Kees-Peter de Roos; Monique R T M Thissen; Luc J Scheijmans; Mieke J Aarts; Simone Oerlemans; Marnix L M Lybeert; Marieke W J Louwman
Journal:  Dermatology       Date:  2019-08-21       Impact factor: 5.366

4.  Automated registration of optical coherence tomography and dermoscopy in the assessment of sub-clinical spread in basal cell carcinoma.

Authors:  A J Coleman; G P Penney; T J Richardson; A Guyot; M J Choi; N Sheth; E Craythorne; A Robson; R Mallipeddi
Journal:  Comput Aided Surg       Date:  2014-05-01

5.  Diagnostic accuracy of confocal microscopy imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma.

Authors:  D J Kadouch; M M Leeflang; Y S Elshot; C Longo; M Ulrich; A C van der Wal; A Wolkerstorfer; M W Bekkenk; M A de Rie
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-08-11       Impact factor: 6.166

6.  Risk factors for complicated Mohs surgery in the South Sweden Mohs Cohort.

Authors:  C Nätterdahl; J Kappelin; B Persson; K Lundqvist; I Ahnlide; K Saleh; Å Ingvar
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-04-12       Impact factor: 9.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.